<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Patent ductus arteriosus (PDA) in preterm infants: Management and outcome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Patent ductus arteriosus (PDA) in preterm infants: Management and outcome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Patent ductus arteriosus (PDA) in preterm infants: Management and outcome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph B Philips III, MD, FAAP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph A Garcia-Prats, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David R Fulton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 29, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H15148221"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>During fetal development, the ductus arteriosus (DA) diverts blood from the pulmonary artery into the aorta, thereby bypassing the lungs  (<a class="graphic graphic_figure graphicRef66765" href="/z/d/graphic/66765.html" rel="external">figure 1</a>). After birth, the DA undergoes active constriction and eventual obliteration. A patent ductus arteriosus (PDA)  (<a class="graphic graphic_figure graphicRef65828" href="/z/d/graphic/65828.html" rel="external">figure 2</a>) occurs when the DA fails to completely close after delivery.</p><p>The management of PDA in preterm infants will be reviewed here. The clinical features and diagnosis of PDA in preterm infants are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5057.html" rel="external">"Patent ductus arteriosus (PDA) in preterm infants: Clinical features and diagnosis"</a>.)</p><p>The diagnosis and management of PDA in term infants, children, and adults are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1421.html" rel="external">"Clinical manifestations and diagnosis of patent ductus arteriosus (PDA) in term infants, children, and adults"</a> and  <a class="medical medical_review" href="/z/d/html/5771.html" rel="external">"Management of patent ductus arteriosus (PDA) in term infants, children, and adults"</a>.)</p><p class="headingAnchor" id="H2508552643"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions of prematurity</strong> – Definitions of different degrees of prematurity based upon gestational age (GA; which is calculated from the first day of the mother's last period) or birth weight (BW) are provided in the table  (<a class="graphic graphic_table graphicRef119362" href="/z/d/graphic/119362.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemodynamically significant PDA</strong> – The definition that we use to define a hemodynamically significant PDA is based upon both clinical findings and echocardiographic measurements. The assessment is based upon multiple findings in combination rather than a single isolated finding. (See  <a class="medical medical_review" href="/z/d/html/5057.html" rel="external">"Patent ductus arteriosus (PDA) in preterm infants: Clinical features and diagnosis", section on 'Hemodynamically significant PDA'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical findings that indicate a hemodynamically significant PDA include need for substantial respiratory support, cardiomegaly and/or pulmonary edema on chest radiograph, hypotension requiring vasopressor support, and evidence of poor perfusion (lactic acidosis, oliguria)  (<a class="graphic graphic_table graphicRef141521" href="/z/d/graphic/141521.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Echocardiographic parameters include PDA diameter &gt;1.5 mm, left atrial and/or ventricular enlargement, and diastolic flow reversal in the abdominal aorta  (<a class="graphic graphic_table graphicRef141537" href="/z/d/graphic/141537.html" rel="external">table 3</a>).</p><p></p><p class="headingAnchor" id="H17050060"><span class="h1">TREATMENT APPROACHES</span><span class="headingEndMark"> — </span>Preterm infants with PDA should be managed collaboratively with input from the neonatal intensive care unit (NICU) team, pediatric cardiologist, and the parents/caregivers. Management decisions should be based on the neonate's entire clinical picture, and not solely on the presence and size of the PDA.</p><p class="headingAnchor" id="H3573677568"><span class="h2">Different approaches</span><span class="headingEndMark"> — </span>There is variability among centers regarding the management of PDAs in preterm infants and the optimal approach is uncertain [<a href="#rid1">1-3</a>]. The two main management approaches include:</p><p class="bulletIndent1"><span class="glyph">●</span>Expectant management with general supportive measures alone initially. (See <a class="local">'Expectant management'</a> below and <a class="local">'General measures'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early pharmacologic therapy using cyclooxygenase (COX) inhibitors (eg, <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a>, <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">indomethacin</a>) or <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a> (paracetamol). (See <a class="local">'Pharmacologic therapy'</a> below.)</p><p></p><p>Other interventions that play a more limited role include:</p><p class="bulletIndent1"><span class="glyph">●</span>Surgical ligation, which is generally reserved for infants with substantial respiratory morbidity who either fail or cannot receive pharmacologic therapy. (See <a class="local">'Surgical ligation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transcatheter closure, which is performed at some specialized centers with expertise and experience performing interventional transcatheter techniques in preterm infants. (See <a class="local">'Transcatheter occlusion'</a> below.)</p><p></p><p>The strategy of prophylactic pharmacologic therapy given to all high-risk extremely preterm (EPT) infants even in the absence of echocardiographic evidence of a hemodynamically significant PDA is <strong>not </strong>recommended. Prophylactic therapy does not appear to reduce the morbidity associated with PDA, and it unnecessarily exposes many infants who would never have developed clinically significant PDAs to the potential harms associated with pharmacologic therapy. (See <a class="local">'Prophylactic therapy'</a> below.)</p><p class="headingAnchor" id="H987673497"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>At the author's center, we use a step-wise management approach for preterm infants with PDA that begins with supportive care alone in most cases  (<a class="graphic graphic_algorithm graphicRef127115" href="/z/d/graphic/127115.html" rel="external">algorithm 1</a>). We prefer this approach because spontaneous closure will occur in many patients. (See <a class="local">'Expectant management'</a> below and <a class="local">'General measures'</a> below.)</p><p>For infants with persistent hemodynamically significant PDAs who remain ventilator-dependent at one week of age, we proceed with a trial of pharmacologic therapy  (<a class="graphic graphic_algorithm graphicRef127115" href="/z/d/graphic/127115.html" rel="external">algorithm 1</a>). We typically use <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> in this setting. Other centers use <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a> (paracetamol) or <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">indomethacin</a>. (See <a class="local">'Pharmacologic therapy'</a> below.)</p><p>If the infant fails two courses of pharmacologic therapy and remains ventilator-dependent, we proceed with a closure procedure (either transcatheter occlusion or surgical ligation)  (<a class="graphic graphic_algorithm graphicRef127115" href="/z/d/graphic/127115.html" rel="external">algorithm 1</a>). In our experience with our current management approach, this is an uncommon scenario. For neonates who require a closure procedure, transcatheter occlusion is the preferred procedure at our institution given the availability of experienced pediatric interventional cardiologists with expertise in this procedure in preterm neonates. In centers without such expertise, surgical ligation is preferred. Surgical ligation is used at our center for infants who are not candidates for transcatheter closure due to severity of lung disease or other practical limitations (eg, size or anatomic limitations). (See <a class="local">'Procedures to close the PDA'</a> below.)</p><p class="headingAnchor" id="H2974079320"><span class="h2">Comparison of approaches</span><span class="headingEndMark"> — </span>The available clinical trial data comparing expectant management versus early pharmacologic treatment in preterm infants with large PDA have demonstrated that while pharmacologic treatment results in earlier closure of the PDA, other clinical outcomes (mortality, bronchopulmonary dysplasia [BPD], necrotizing enterocolitis [NEC]) are generally similar between the two approaches [<a href="#rid4">4-10</a>]. </p><p>In a meta-analysis of six trials including 500 EPT infants with hemodynamically significant PDA (variably defined; the two most common echocardiographic criteria were diameter &gt;1.5 mm and/or left atrial enlargement), mortality rates were similar in those managed with expectant management compared with early (within seven days after birth) pharmacologic treatment (11 versus 9 percent; relative risk [RR] 1.25, 95% CI 0.72-2.17) [<a href="#rid9">9</a>]. Rates of BPD were also similar in both groups (26 versus 24 percent; RR 1.11, 95% CI 0.78-1.6). Stage 2 or greater NEC occurred less commonly in the expectant management group (3 versus 7 percent), but the difference was not statistically significant (RR 0.43, 95% CI 0.16-1.2). In a separate analysis of seven trials (384 participants) comparing expectant management with very early (within 72 hours after birth) pharmacologic treatment, mortality rates were similar in both groups (17 versus 16 percent; RR 1.06, 95% CI 0.65-1.72) as were rates of BPD and other morbidities [<a href="#rid9">9</a>]. </p><p>Additional support for the expectant management approach comes from five subsequent clinical trials not included in the meta-analyses [<a href="#rid4">4,6-8,10</a>]. All five trials allowed for rescue therapy, though the criteria for rescue therapy varied. Taken together, these data suggest that while early pharmacologic treatment results in earlier closure of the PDA, this does not appear to convey a meaningful clinical benefit with regard to survival, neonatal morbidities, or long-term neurodevelopmental outcomes.</p><p>The largest trial to address this question was the Baby-OSCAR trial, which involved 653 EPT infants with large PDA who were randomly assigned to early <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> therapy or placebo starting within 72 hours after birth [<a href="#rid10">10</a>]. After the initial course of the study drug, infants in both arms could be treated with open-label medical or surgical treatment if they had symptoms attributable to PDA. At three weeks of age, more infants in the early ibuprofen group had a closed or small PDA (56 versus 37 percent; RR 1.50, 95% CI 1.26-1.79). However, the trial did not detect a difference in mortality at 36 weeks postmenstrual age (13.6 percent in the early treatment group versus 10.3 percent in the placebo group; RR 1.32, 95% CI 0.92-1.90) nor in rates of moderate-to-severe BPD (64 versus 59 percent; RR 1.09, 95% CI 0.96-1.23). Both groups also had similar rates of other neonatal morbidities, including grade III or IV intraventricular hemorrhage (IVH) (14 versus 11 percent), retinopathy of prematurity (ROP) (14 percent in both groups), severe NEC (13 percent in both groups), and pulmonary hemorrhage (8 versus 6 percent). Patients in the early treatment group less frequently received rescue medical therapy (13 versus 26 percent) or surgical intervention for PDA (3 versus 10 percent).</p><p>Similar findings were reported in four earlier randomized trials [<a href="#rid4">4,6-8</a>].</p><p>Long-term outcomes were reported in one trial involving 337 EPT infants with large PDA who were randomly assigned to early <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> therapy or placebo starting within 12 hours after birth [<a href="#rid7">7</a>]. At 24 months corrected age, the number of patients who were alive without cerebral palsy was similar in both groups (71 percent in the early treatment group versus 72 percent in the placebo group; RR 0.98, 95% CI 0.83-1.16).</p><p>Observational studies comparing outcomes in neonates managed with expectant versus pharmacologic treatment have reached variable conclusions [<a href="#rid11">11-23</a>]. Differences in the findings in these studies may be due to differences in the population studied (eg, gestational age, severity of illness), criteria used for intervention, and the era in which they were conducted.</p><p class="headingAnchor" id="H1224178343"><span class="h2">Goals of treatment</span><span class="headingEndMark"> — </span>The goals of management are to:</p><p class="bulletIndent1"><span class="glyph">●</span>Reduce morbidity from the effects of excessive left-to-right shunting and ductal steal. (See  <a class="medical medical_review" href="/z/d/html/5057.html" rel="external">"Patent ductus arteriosus (PDA) in preterm infants: Clinical features and diagnosis", section on 'Consequences of a PDA'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoid unnecessary treatment in neonates who will likely have spontaneous closure without any adverse sequelae of the PDA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ensure timely treatment of PDA in infants for whom the PDA is likely contributing to significant respiratory disease and/or other neonatal morbidity.</p><p></p><p>Identifying which infants are most likely to benefit from intervention remains a challenge. (See <a class="local">'Unanswered questions'</a> below.)</p><p>In a multicenter international study involving nearly 40,000 EPT neonates managed at 139 NICUs, there was U-shaped relationship between rates of treatment for PDA (pharmacologic or surgical) at each NICU and mortality rates, with higher mortality at centers with the lowest and highest rates of treatment for PDA [<a href="#rid24">24</a>]. A similar U-shaped relationship was seen for neurologic outcome. These U-shaped relationships suggest that if the threshold for intervention is too high, there can be adverse consequences, likely due to the hemodynamic effects of untreated significant PDA. At the same time, if the threshold for intervention is too low, there may be adverse consequences related to unnecessary treatment of infants with mild or clinically insignificant PDA.</p><p class="headingAnchor" id="H223266277"><span class="h2">Unanswered questions</span><span class="headingEndMark"> — </span>Ongoing challenges and unanswered questions in the management of PDA in preterm neonates include:</p><p class="bulletIndent1"><span class="glyph">●</span>What criteria should be used to define hemodynamically significant PDA? The definition is not standardized and there was considerable variability in the definitions used in the clinical trials discussed above. We generally favor a definition that includes both clinical and echocardiographic criteria. This is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5057.html" rel="external">"Patent ductus arteriosus (PDA) in preterm infants: Clinical features and diagnosis", section on 'Hemodynamically significant PDA'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Is it possible to identify an at-risk population who may benefit from early pharmacologic treatment? For example, some have advocated for early treatment in the most premature neonates (eg, GA &lt;25 weeks) since these neonates are at high risk of experiencing complications, and the likelihood of spontaneous closure is lower than in more mature neonates. (See  <a class="medical medical_review" href="/z/d/html/5057.html" rel="external">"Patent ductus arteriosus (PDA) in preterm infants: Clinical features and diagnosis", section on 'Spontaneous ductal closure after birth'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If an expectant management approach is used, what threshold should be used for intervention if the PDA does not close spontaneously? The clinical trials described above used variable criteria for providing rescue therapy. As a result, use of rescue therapy varied widely in these trials, from as low as 6 percent to as high as 62 percent [<a href="#rid4">4,6-8</a>]. The optimal threshold remains uncertain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When pharmacologic treatment is used, what endpoint should be targeted (is complete ductal closure necessary or is improvement in clinical status sufficient)?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>What criteria should be used for performing a closure procedure (transcatheter occlusion or ligation)?</p><p></p><p class="headingAnchor" id="H1214585"><span class="h1">GENERAL MEASURES</span><span class="headingEndMark"> — </span>General measures that are provided in all neonates with PDA include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neutral thermal environment</strong> – A neutral thermal environment that minimizes metabolic demands on ventricular function. (See  <a class="medical medical_review" href="/z/d/html/4965.html" rel="external">"Overview of short-term complications in preterm infants", section on 'Hypothermia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory support</strong> – Respiratory support is tailored according to the neonate's degree of respiratory compromise. Details are provided separately. (See  <a class="medical medical_review" href="/z/d/html/5067.html" rel="external">"Respiratory support, oxygen delivery, and oxygen monitoring in the newborn"</a> and  <a class="medical medical_review" href="/z/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Ongoing respiratory support'</a> and  <a class="medical medical_review" href="/z/d/html/4977.html" rel="external">"Bronchopulmonary dysplasia (BPD): Management and outcome", section on 'Respiratory support'</a>.)</p><p></p><p class="bulletIndent1">For infants who require mechanical ventilation, care should be taken to minimize the risk of ventilator-induced lung injury, as summarized in the table  (<a class="graphic graphic_table graphicRef131155" href="/z/d/graphic/131155.html" rel="external">table 4</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/130240.html" rel="external">"Approach to mechanical ventilation in very preterm neonates"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring for signs of anemia</strong> – The thresholds for transfusion in infants with PDA are the same as for the general preterm neonatal population, as summarized in the figure  (<a class="graphic graphic_table graphicRef140490" href="/z/d/graphic/140490.html" rel="external">table 5</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5041.html" rel="external">"Red blood cell (RBC) transfusions in the neonate"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluid restriction with or without diuretic therapy</strong> – Excessive fluid administration (&gt;170 mL/kg per day) is associated with an increased incidence of PDA [<a href="#rid25">25</a>]. Our usual practice is to restrict total fluid intake to 130 to 140 mL/kg per day. A more restrictive limit may be warranted if there are overt signs of pulmonary edema. The fluid status of the patient must be monitored frequently to avoid under- or overhydration as fluid needs widely vary in preterm infants due to differences in insensible fluid loss. (See  <a class="medical medical_review" href="/z/d/html/5065.html" rel="external">"Fluid and electrolyte therapy in newborns"</a> and  <a class="medical medical_review" href="/z/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Fluid management'</a>.) </p><p></p><p class="bulletIndent1">Use of diuretic therapy is generally limited to infants with significant respiratory morbidity (ie, bronchopulmonary dysplasia [BPD]), as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4977.html" rel="external">"Bronchopulmonary dysplasia (BPD): Management and outcome", section on 'Diuretics'</a>.)</p><p></p><p class="bulletIndent1">If diuretic therapy is used, <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">furosemide</a> and other loop diuretics are generally avoided in the first one to two weeks after birth. This is because loop diuretics stimulate renal synthesis of prostaglandin E<sub>2</sub>, a potent vasodilator that maintains ductal patency [<a href="#rid26">26</a>].</p><p></p><p class="headingAnchor" id="H1744217938"><span class="h1">EXPECTANT MANAGEMENT</span><span class="headingEndMark"> — </span>Expectant management consists of the supportive care measures described above and close clinical monitoring. (See <a class="local">'General measures'</a> above.)</p><p>Most neonates managed expectantly will have spontaneous closure of the PDA. The expected time to spontaneous closure increases with decreasing gestational age [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/5057.html" rel="external">"Patent ductus arteriosus (PDA) in preterm infants: Clinical features and diagnosis", section on 'Spontaneous ductal closure after birth'</a>.) </p><p>However, some infants may require rescue therapy due to ongoing moderate to severe symptoms. The optimal threshold for starting therapy in this setting is uncertain and practice varies. Our suggested approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinically stable neonates</strong> – Neonates who remain clinically stable with only modest respiratory support requirements (ie, continuous positive airway pressure, other noninvasive ventilation modality, or less intensive support) and without signs of systemic hypoperfusion (eg, oliguria, acidosis) generally do not require any intervention to close the PDA. Follow-up echocardiogram is performed at 36 weeks postmenstrual age (or sooner if any concerns arise). If the PDA has closed by that time, no further evaluation is necessary. If the PDA persists, a repeat echocardiogram is performed before neonatal intensive care unit (NICU) discharge to determine need for post-discharge follow-up.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neonates with clinical concern for persistent hemodynamically significant PDA </strong>–<strong> </strong>Neonates who remain ventilator-dependent at one week of age and those with hemodynamic instability attributable to the PDA should have a repeat echocardiogram performed to confirm that there is a persistent hemodynamically significant PDA. If the echocardiogram confirms persistence of a hemodynamically significant PDA, we proceed with a trial of pharmacologic therapy (see <a class="local">'Pharmacologic therapy'</a> below). If the echocardiogram findings suggest only a small or trivial PDA, the neonate should be evaluated for other causes of their clinical instability.</p><p></p><p>The evidence supporting expectant management is summarized above. (See <a class="local">'Comparison of approaches'</a> above.) </p><p>Our center uses a seven-day threshold for initiating medical therapy in ventilator-dependent neonates with PDA. Other centers may use different thresholds (eg, some may start treatment at 72 hours in intubated high-risk extremely preterm neonates). The rationale for the threshold we use at our center is based upon observational data suggesting that the risk of bronchopulmonary dysplasia (BPD) in mechanically ventilated neonates increases sharply when the PDA persists for ≥7 days [<a href="#rid27">27</a>]. These data are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5057.html" rel="external">"Patent ductus arteriosus (PDA) in preterm infants: Clinical features and diagnosis", section on 'Consequences of a PDA'</a>.)</p><p class="headingAnchor" id="H3141754076"><span class="h1">PHARMACOLOGIC THERAPY</span><span class="headingEndMark"> — </span>Pharmacologic therapy is directed towards inhibiting prostaglandin synthetase, as prostaglandin E<sub>2</sub> (PGE<sub>2</sub>), which has two catalytic sites, promotes ductal patency. The nonselective cyclooxygenase (COX) inhibitors (<a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> and <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">indomethacin</a>) inhibit the COX site, whereas <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a> (paracetamol) affects the peroxidase segment. </p><p class="headingAnchor" id="H3160253696"><span class="h2">Indications</span><span class="headingEndMark"> — </span>As previously discussed, different neonatal intensive care units (NICUs) use different thresholds for initiating pharmacologic therapy for treatment of PDA in preterm neonates. In many NICUs (including the author's institution), initial management is supportive, and pharmacologic therapy is reserved for symptomatic infants with persistent hemodynamically significant PDAs  (<a class="graphic graphic_algorithm graphicRef127115" href="/z/d/graphic/127115.html" rel="external">algorithm 1</a>). However, other NICUs prefer a strategy of early treatment in which pharmacologic therapy is used in any extremely preterm (EPT) neonate diagnosed with a large PDA in the first 24 to 48 hours after birth [<a href="#rid28">28</a>]. The optimal approach is uncertain. (See <a class="local">'Treatment approaches'</a> above and <a class="local">'Comparison of approaches'</a> above.)</p><p class="headingAnchor" id="H3366926790"><span class="h2">Choice of regimen</span><span class="headingEndMark"> — </span>The choice of regimen is highly center-specific [<a href="#rid3">3</a>]. All three agents appear to have similar efficacy, though <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> and <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a> likely have fewer adverse effects compared with <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">indomethacin</a> [<a href="#rid29">29-31</a>]. (See <a class="local">'Comparative data'</a> below.) </p><p>Considerations that factor into decision-making include:</p><p class="bulletIndent1"><span class="glyph">●</span>Cost and availability of each drug</p><p class="bulletIndent1"><span class="glyph">●</span>Whether the neonate is tolerating enteral feeds</p><p class="bulletIndent1"><span class="glyph">●</span>Whether the neonate has any absolute or relative contraindications to treatment with a nonselective COX inhibitor (active bleeding, acute kidney injury [AKI]) (see <a class="local">'Contraindications'</a> below)</p><p></p><p>At the author's center, when pharmacologic therapy is used, we preferentially use standard-dose <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> (10 mg/kg for the first dose administered intravenously [IV] or enterally, followed by two doses of 5 mg/kg given every 24 hours). A second course is given if the follow-up echocardiogram shows failure of PDA closure and the infant is still ventilator-dependent  (<a class="graphic graphic_algorithm graphicRef127115" href="/z/d/graphic/127115.html" rel="external">algorithm 1</a>). (See <a class="local">'Ibuprofen'</a> below and <a class="local">'Response to therapy'</a> below.)</p><p>For patients with contraindications to <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a>, we use <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a> (paracetamol). (See <a class="local">'Contraindications'</a> below and <a class="local">'Acetaminophen (paracetamol)'</a> below.)</p><p><a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">Acetaminophen</a> is increasingly used as a first-line agent at many centers. By contrast, use of <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">indomethacin</a> has declined since the early 2000s given the availability of IV <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> and acetaminophen, which have fewer adverse effects. (See <a class="local">'Acetaminophen (paracetamol)'</a> below and <a class="local">'Indomethacin'</a> below.)</p><p class="headingAnchor" id="H426088088"><span class="h2">Comparative data</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ibuprofen</strong><strong> versus </strong><strong>indomethacin</strong> – <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">Ibuprofen</a> and <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">indomethacin</a> appear to have similar efficacy for achieving PDA closure, but the risk of adverse effects (acute kidney injury [AKI], necrotizing enterocolitis [NEC]) is lower with ibuprofen [<a href="#rid1">1,29</a>]. In a meta-analysis of 24 clinical trials (1590 neonates), ibuprofen (administered IV or enterally) and indomethacin had similar efficacy for achieving PDA closure after the first treatment course (success rates of 70 and 72 percent, respectively; relative risk [RR] 0.93, 95% CI 0.81-1.1) [<a href="#rid29">29</a>]. Infants treated with ibuprofen were less likely to develop NEC (7 versus 11 percent; RR 0.68, 95% CI 0.49-0.94) or oliguria (3 versus 12 percent; RR 0.28, 95% CI 0.14-0.54). Mortality was similar in both groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ibuprofen</strong><strong> versus </strong><strong>acetaminophen</strong><strong> (paracetamol)</strong> – <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">Ibuprofen</a> and <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a> appear to have similar efficacy for achieving PDA closure; however, the risk of occult gastrointestinal bleeding appears to be higher with ibuprofen [<a href="#rid31">31-36</a>]. In a meta-analysis of five trials (559 neonates), ibuprofen and acetaminophen had similar efficacy for achieving PDA closure after the first treatment course (success rates of 67 and 69 percent, respectively; RR 0.95, 95% CI 0.75-1.2) [<a href="#rid31">31</a>]. Infants treated with ibuprofen had higher creatinine levels and were more likely to develop occult blood in their stools (8 versus 2 percent; RR 3.6, 95% CI 1.4-8.3). The clinical significance of these findings is debatable. Mortality was similar in both groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acetaminophen</strong><strong> (paracetamol) versus </strong><strong>indomethacin</strong> – Based on limited clinical trial data, <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a> and <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">indomethacin</a> appear to have similar efficacy for achieving PDA closure [<a href="#rid31">31</a>]; the risk of adverse effects is likely higher with indomethacin. In a meta-analysis of two trials (273 neonates), acetaminophen and indomethacin had similar efficacy for achieving PDA closure by the end of treatment (success rates of 85 percent in both groups) [<a href="#rid31">31</a>]. </p><p></p><p>The relative efficacy of different regimens used to treat PDA in preterm neonates has been examined in network meta-analyses, which estimate treatment effects based upon direct and indirect comparisons in the available clinical trials [<a href="#rid37">37,38</a>]. In a network meta-analysis of 68 randomized trials comparing various treatment regimens (including <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">indomethacin</a>, standard- and high-dose IV <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a>, standard- and high-dose oral ibuprofen, oral <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a> [paracetamol], and placebo [ie, expectant management]), high-dose oral or IV ibuprofen appeared to be among the most effective regimens for achieving PDA closure within seven days of starting therapy (based upon estimates from 17 direct comparisons and 45 indirect comparisons) [<a href="#rid37">37</a>]. For example, high-dose oral ibuprofen was more likely to achieve PDA closure compared with IV indomethacin (odds ratio [OR] 2.35, 95% CI 1.08-5.31). The differences were not statistically significant when compared with oral acetaminophen (OR 1.23, 95% CI 0.62-2.48) or standard-dose oral ibuprofen (OR 1.63, 95% CI 0.84-3.24). There were no statistically significant differences in mortality or rates of bronchopulmonary dysplasia (BPD) or NEC between any of the different treatment regimens, including placebo (expectant management). An important limitation of these data is that the analyses rely on the assumption of transitivity (ie, that the trial populations, interventions, cointerventions, and assessment of outcomes were sufficiently similar in all of these trials). Given the large number of included clinical trials that spanned multiple different eras, the transitivity assumption is unlikely to hold up. Thus, the certainty of these findings is low.</p><p class="headingAnchor" id="H1528211653"><span class="h2">Specific agents</span></p><p class="headingAnchor" id="H230984984"><span class="h3">Ibuprofen</span></p><p class="headingAnchor" id="H230985068"><span class="h4">Dose</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">Ibuprofen</a> can be administered enterally or IV using a standard- or high-dose regimen. In our practice, we use the standard-dose regimen. The available clinical trial data suggest that the high-dose regimen is more effective for achieving PDA closure at the end of treatment; however, it is also associated with higher risk of adverse effects (eg, AKI, gastrointestinal bleeding, NEC) [<a href="#rid29">29</a>]. (See <a class="local">'Comparative data'</a> above.) </p><p class="bulletIndent1"><span class="glyph">●</span>Standard-dose regimen – The standard-dose regimen consists of an initial dose of 10 mg/kg given enterally or IV followed by two additional doses of 5 mg/kg given at 24-hour intervals. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High-dose regimen – The high-dose regimen consists of an initial dose of 15 to 20 mg/kg given enterally of IV followed by two additional doses of 7.5 to 10 mg/kg administered at 12- to 24-hour intervals. </p><p></p><p>IV and enteral administration of <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> appear to be equally effective for PDA closure [<a href="#rid29">29</a>]. In resource abundant settings, the IV product is typically used for treating PDA in preterm neonates. However, IV ibuprofen is costly and may not be available in all settings. Thus, some neonatal units may prefer the enteral product.</p><p class="headingAnchor" id="H502249843"><span class="h4">Contraindications</span><span class="headingEndMark"> — </span>The following contraindications apply to both <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> and <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">indomethacin</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>Absolute contraindications:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>AKI (serum creatinine &gt;1 mg/dL [88.4 micromol/L])</p><p class="bulletIndent2"><span class="glyph">•</span>Active bleeding, especially active intracranial hemorrhage or gastrointestinal bleeding</p><p class="bulletIndent2"><span class="glyph">•</span>NEC (proven or clinically suspected) </p><p class="bulletIndent2"><span class="glyph">•</span>Ductal-dependent congenital heart disease (CHD) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Relative contraindications – We also generally avoid <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> (and <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">indomethacin</a>) in the following scenarios: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Thrombocytopenia and/or coagulopathy – We do not routinely measure platelet counts or coagulation studies prior to drug administration if there is no clinical concern for coagulopathy. However, if the infant has documented thrombocytopenia or coagulopathy, we avoid <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> (and <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">indomethacin</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute infection (proven or suspected).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oliguria (urine output &lt;1 cc/kg per hour).</p><p></p><p>In most of these circumstances, if the infant requires pharmacotherapy for PDA closure, we use <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a> (paracetamol) (see <a class="local">'Acetaminophen (paracetamol)'</a> below). The exception is infants with ductal-dependent CHD since they generally require medical therapy to maintain ductal patency rather than therapy to close the PDA. In fact, closure of the PDA in a newborn with ductal-dependent CHD can be life-threatening. (See  <a class="medical medical_review" href="/z/d/html/5774.html" rel="external">"Identifying newborns with critical congenital heart disease", section on 'Ductal-dependent lesions'</a>.)</p><p class="headingAnchor" id="H959457279"><span class="h4">Adverse effects</span><span class="headingEndMark"> — </span>Potential adverse effects associated with nonselective COX inhibitors include [<a href="#rid39">39-41</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>AKI</p><p class="bulletIndent1"><span class="glyph">●</span>Bleeding, particularly gastrointestinal bleeding</p><p class="bulletIndent1"><span class="glyph">●</span>NEC</p><p class="bulletIndent1"><span class="glyph">●</span>Spontaneous intestinal perforation</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperbilirubinemia, due to displacement of bilirubin from binding sites on albumin; however, this has been reported only with drug levels that far exceed those used clinically [<a href="#rid42">42-45</a>]</p><p></p><p><a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">Ibuprofen</a> is associated with a lower risk of gastrointestinal and renal side effects than <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">indomethacin</a> [<a href="#rid29">29</a>]; however, these remain potential risks associated with both drugs. Some of these adverse effects occur due to reduced cerebral, gastrointestinal, and renal blood flow caused by nonselective COX inhibitors. This blood flow reduction is greater with indomethacin compared with ibuprofen, which may explain why ibuprofen has a better safety profile [<a href="#rid46">46-49</a>]. </p><p class="headingAnchor" id="H3746355507"><span class="h4">Feeding during treatment</span><span class="headingEndMark"> — </span>Because of the potential adverse effects of <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> or <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">indomethacin</a> on the gastrointestinal tract, there have been concerns about initiation or continuation of enteral feeds during administration of either drug. However, several studies have shown that enteral feeding during treatment is safe [<a href="#rid50">50-52</a>]. As a result, we continue enteral feedings while on treatment.</p><p class="headingAnchor" id="H1548957240"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>The efficacy of <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> for treatment of PDA in preterm neonates is supported by clinical trials and meta-analyses [<a href="#rid29">29,53</a>]. These data are discussed above:</p><p class="bulletIndent1"><span class="glyph">●</span>Compared with placebo (expectant management) (see <a class="local">'Comparison of approaches'</a> above)</p><p class="bulletIndent1"><span class="glyph">●</span>Compared with other agents (see <a class="local">'Comparative data'</a> above)</p><p></p><p class="headingAnchor" id="H1214592"><span class="h3">Indomethacin</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">Indomethacin</a> is usually given IV and more than one dose is typically required for sustained constriction. Various dosing regimens have been described, ranging from 0.1 and 0.2 mg/kg per dose administered at 12- to 24-hour intervals. </p><p>Commonly used dosing regimens include [<a href="#rid37">37,54,55</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Standard weight-based dosing – Three doses of 0.2 mg/kg per dose given IV at 12-hour intervals. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dosing based on postnatal age:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants &lt;48 hours of age – The first dose is 0.2 mg/kg IV for the first dose, followed by two additional doses of 0.1 mg/kg given IV at 12-hour intervals. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants &gt;48 hours and &lt;7 days – Three total doses of 0.2 mg/kg per dose given IV at 12-hour intervals.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants ≥7 days of age – Three total doses of 0.25 mg/kg per dose given IV at 12-hour intervals.</p><p></p><p>More prolonged treatment courses (ie, &gt;3 doses) should generally be avoided since this increases the risk of NEC and does not appear to increase the likelihood of PDA closure [<a href="#rid56">56</a>].</p><p>Measuring plasma drug levels is not necessary and this testing is not widely available.</p><p>Contraindications to <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">indomethacin</a> are the same as for <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a>. The approach to enteral feeding while on treatment is also the same. (See <a class="local">'Contraindications'</a> above and <a class="local">'Feeding during treatment'</a> above.)</p><p>Adverse effects are generally similar to those of <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a>. However, <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">indomethacin</a> is associated with a higher risk of AKI and NEC compared with ibuprofen [<a href="#rid1">1,29</a>]. (See <a class="local">'Adverse effects'</a> above.)</p><p class="headingAnchor" id="H1358959645"><span class="h3">Acetaminophen (paracetamol)</span><span class="headingEndMark"> — </span>Accumulating evidence suggests that both oral and IV <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a> are reasonable alternatives to nonselective COX inhibitor therapy in preterm infants with PDA [<a href="#rid31">31,57</a>]. In our practice, we use acetaminophen for patients in whom nonselective COX inhibitor therapy is contraindicated (see <a class="local">'Contraindications'</a> above). Other centers use acetaminophen as the first-line agent. (See <a class="local">'Choice of regimen'</a> above and <a class="local">'Comparative data'</a> above.)</p><p>The dosing regimen for PDA closure consists of 15 mg/kg per dose given IV or enterally every six hours for three to seven days [<a href="#rid31">31,34,58</a>]. </p><p>After the third day of therapy, an echocardiogram is performed to see if there has been a response to therapy. If the PDA is closed, therapy can be discontinued. However, if it remains open, <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a> is continued for a full seven days of treatment. Infants requiring a seven-day course should have liver function tests monitored. </p><p class="headingAnchor" id="H1816979689"><span class="h2">Response to therapy</span><span class="headingEndMark"> — </span>The response to therapy is assessed based on the neonate's clinical status and repeat echocardiogram performed 24 to 48 hours after completion of the treatment course. For neonates treated with <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a> (paracetamol), an echocardiogram is obtained after the third day of treatment to determine if a full seven-day treatment course is necessary. If the PDA has not closed, treatment is continued, and a follow-up echocardiogram is obtained after treatment is completed.</p><p>Once treatment is completed, if the PDA has closed or reduced to small or trivial size, treatment is considered successful, and no further intervention is required. </p><p>If the infant continues to have a hemodynamically significant PDA and remains symptomatic (eg, ongoing ventilator dependence), treatment is considered unsuccessful and a second treatment course is administered, as discussed below. (See <a class="local">'Treatment failure'</a> below.) </p><p class="headingAnchor" id="H2656021194"><span class="h2">Treatment failure</span><span class="headingEndMark"> — </span>Approximately 25 to 40 percent of medically treated patients fail to respond to the initial treatment course [<a href="#rid29">29-31</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Risk factors for treatment failure include [<a href="#rid59">59,60</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lower gestational age (GA)</p><p class="bulletIndent2"><span class="glyph">•</span>Lack of exposure to antenatal glucocorticoid therapy</p><p class="bulletIndent2"><span class="glyph">•</span>Severe respiratory disease</p><p class="bulletIndent2"><span class="glyph">•</span>Postnatal age &gt;1 month</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Retreatment</strong> – If the infant continues to have a hemodynamically significant PDA and remains symptomatic (eg, ongoing ventilator dependence), a second course of treatment can be given either using the same agent or a different agent. Approximately 40 to 50 percent of patients who fail initial therapy will respond to a second course [<a href="#rid61">61-63</a>]. </p><p></p><p class="bulletIndent1">Studies on the use of combination therapy (eg, <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> plus <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a>) for patients with persistent PDA have reached variable conclusions [<a href="#rid64">64,65</a>]. Taken together, the available studies suggest that combination therapy probably does not result in higher rates of PDA closure compared with single-agent therapy [<a href="#rid64">64</a>]. Thus, we suggest not using this approach.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory patients</strong> – For patients who fail to respond to two courses of therapy, subsequent treatment courses are unlikely to close the PDA. If the infant remains symptomatic from the PDA (eg, ventilator-dependent), a definitive closure procedure (surgical ligation or transcatheter occlusion) is generally warranted. (See <a class="local">'Procedures to close the PDA'</a> below.)</p><p></p><p class="headingAnchor" id="H747537949"><span class="h1">PROCEDURES TO CLOSE THE PDA</span><span class="headingEndMark"> — </span>Procedural closure options include transcatheter occlusion and surgical ligation. In the modern era, these procedures are seldom required and are reserved for infants with symptomatic large PDAs who fail to respond to pharmacologic therapy.</p><p class="headingAnchor" id="H1214649"><span class="h2">Surgical ligation</span><span class="headingEndMark"> — </span>Surgical ligation is performed via posterolateral thoracotomy. Some surgeons perform multiple ligations or divisions to minimize the risk of recurrent shunt [<a href="#rid66">66</a>].</p><p>Postoperative care includes continuous cardiovascular monitoring and hemodynamic support to maintain adequate blood pressure and perfusion [<a href="#rid67">67</a>]. Serial echocardiography may be used to assess postoperative cardiac function and guide management.</p><p>Risks associated with PDA ligation include [<a href="#rid11">11,68,69</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemodynamic instability and low cardiac output (sometimes called post-ligation cardiac syndrome) [<a href="#rid70">70</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Hemorrhage</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory deterioration</p><p class="bulletIndent1"><span class="glyph">●</span>Infection</p><p class="bulletIndent1"><span class="glyph">●</span>Intraventricular hemorrhage (IVH)</p><p class="bulletIndent1"><span class="glyph">●</span>Chylothorax</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent laryngeal nerve paralysis</p><p class="bulletIndent1"><span class="glyph">●</span>Pneumothorax</p><p></p><p>It remains uncertain whether the surgical ligation procedure itself is a major contributor to morbidity and mortality. Most patients who undergo surgical ligation are more severely compromised to begin with and thus outcomes for this population are generally less favorable compared with those who do not require PDA ligation. (See <a class="local">'Outcome'</a> below.) </p><p>In a multicenter retrospective study of 754 infants &lt;28 weeks GA with hemodynamically significant PDA managed medically (n = 570) or with surgical ligation (n = 184), those who underwent ligation had higher rates of neonatal comorbidities prior to treatment (eg, mechanical ventilation dependence, sepsis, necrotizing enterocolitis) [<a href="#rid71">71</a>]. Fewer patient in the surgical ligation survived to age 18 to 24 months without moderate to severe neurologic disability (40 versus 48 percent); however, after adjusting for other confounders, the difference was not statistically significant (adjusted odds ratio (aOR) 0.97; 95% CI 0.65-1.44).</p><p>Similarly, a retrospective study from a single center of 166 extremely preterm (EPT) infants who underwent surgical ligation and 142 EPT infants who did not found that, after adjusting for other confounders, PDA ligation was not independently associated with increased risk of adverse outcome (neurodevelopmental impairment, bronchopulmonary dysplasia [BPD], or retinopathy of prematurity [ROP]) [<a href="#rid72">72</a>]. In a follow-up report from the same center, 157 of 166 EPT infants treated with surgical ligation survived and were successfully extubated (median 12 days after ligation) [<a href="#rid73">73</a>]. Of note, earlier extubation was associated with larger PDA diameter and moderate to severe left ventricular dilatation, suggesting that the PDA was a significant contributor to the respiratory failure in these infants. </p><p class="headingAnchor" id="H1911187651"><span class="h2">Transcatheter occlusion</span><span class="headingEndMark"> — </span>Transcatheter PDA occlusion has been performed in both term and preterm infants, including preterm extremely low birth weight (ELBW; &lt;1000 g) neonates [<a href="#rid74">74-79</a>]. The procedure is usually performed using access through the femoral artery or vein. </p><p>In 2019, the US Food and Drug Administration (FDA) approved the Amplatzer Piccolo Occluder for use in infants weighing &gt;700 g and age &gt;3 days [<a href="#rid80">80</a>]. </p><p>Experience with this procedure is growing, and it is performed in some specialized centers with experienced pediatric interventional cardiologists [<a href="#rid81">81</a>]. </p><p>In a systematic review and meta-analysis that included of 28 studies (mostly small retrospective case series) including a total of 373 infants ≤1.5 kg who underwent transcatheter PDA closure, the procedure was successfully completed in 96 percent of cases [<a href="#rid82">82</a>]. The pooled rate of major adverse events was 8 percent, including 5 deaths (1.3 percent) related to the procedure. Minor adverse events occurred in 18 percent.</p><p>The relative frequencies of procedure-related complications reported in studies of transcatheter device PDA closure with the Piccolo Occluder in ELBW infants include [<a href="#rid83">83</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Device embolization (3 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Aortic obstruction or narrowing (1 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Obstruction of the left pulmonary artery (1 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Tricuspid regurgitation (3 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Vascular injury (1 percent)</p><p></p><p>Cardiorespiratory instability can occur after transcutaneous PDA closure, similar to the post-ligation cardiac syndrome described after surgical ligation [<a href="#rid84">84</a>].</p><p class="headingAnchor" id="H1214679"><span class="h1">PROPHYLACTIC THERAPY</span><span class="headingEndMark"> — </span>We suggest <strong>not</strong> routinely using prophylactic pharmacologic therapy to reduce the incidence of PDA. Prophylactic treatment does not appear to reduce the morbidity associated with PDA and it unnecessarily exposes infants without significant PDA to the potential adverse effects of pharmacologic therapy [<a href="#rid9">9,53,85-90</a>]. </p><p>In a meta-analysis of eight trials (1791 extremely preterm [EPT] neonates), prophylactic <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">indomethacin</a> therapy reduced the need for invasive PDA closure (relative risk [RR] 0.51, 95% CI 0.37-0.71), but there was no impact on mortality or neurodevelopmental impairment (RR 1.02, 95% CI 0.90-1.15) [<a href="#rid53">53</a>]. Similarly, in a meta-analysis of seven trials (925 EPT neonates), prophylactic <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> therapy reduced the need for invasive PDA closure (RR 0.46, 95% CI 0.22-0.96), without any clear benefit with regards to survival or neurodevelopmental outcome [<a href="#rid53">53</a>]. There are limited data on prophylactic <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a> therapy [<a href="#rid91">91</a>], but it is likely to have the same results as the other two agents.</p><p class="headingAnchor" id="H1214695"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>Preterm infants with clinically significant PDAs have a higher risk of mortality and neonatal morbidity (eg, bronchopulmonary dysplasia [BPD], intraventricular hemorrhage [IVH], necrotizing enterocolitis [NEC]) compared with neonates of similar gestational age and birth weight without PDAs [<a href="#rid92">92-94</a>]. (See  <a class="medical medical_review" href="/z/d/html/5057.html" rel="external">"Patent ductus arteriosus (PDA) in preterm infants: Clinical features and diagnosis", section on 'Consequences of a PDA'</a>.)</p><p>As discussed above, the risk of mortality and morbidity appear to be similar regardless of whether the infant is managed expectantly or with early pharmacologic therapy. (See <a class="local">'Comparison of approaches'</a> above.)</p><p>Outcomes are generally worse for infants who require surgical ligation, which likely reflects that this is a more severely compromised patient population [<a href="#rid11">11,13,95,96</a>]. </p><p class="headingAnchor" id="H47818026"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management approach</strong> – For most preterm neonates with PDA, we suggest expectant supportive care initially rather than early pharmacologic therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This is because spontaneous closure will occur in many cases. While pharmacologic treatment results in earlier closure of the PDA, this does not appear to convey a meaningful clinical benefit in terms of survival, neonatal morbidities, or long-term neurodevelopmental outcomes. However, the optimal management approach is uncertain, and some centers prefer a strategy of early pharmacologic therapy. (See <a class="local">'Expectant management'</a> above and <a class="local">'Comparison of approaches'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care</strong> – General supportive care measures provided to all preterm infants with PDA include a neutral thermal environment, optimal respiratory support, monitoring for anemia, and modest fluid restriction. (See <a class="local">'General measures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ongoing clinical concern for hemodynamically significant PDA</strong> – For patients with a persistent hemodynamically significant PDA  (<a class="graphic graphic_table graphicRef141537" href="/z/d/graphic/141537.html" rel="external">table 3</a>) who remain ventilator-dependent at one week of age or with signs of hemodynamic instability (eg, hypotension requiring vasoactive therapy, oliguria, lactic acidosis) not otherwise explained, we suggest pharmacologic treatment to close the PDA rather than ongoing supportive care alone (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of agent</strong> – We suggest either <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> or <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a> (paracetamol) rather than <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">indomethacin</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, indomethacin is a reasonable option, particularly if the costs of intravenous (IV) ibuprofen and acetaminophen are a limitation. All three agents appear to have similar efficacy; indomethacin has a higher risk of adverse effects (eg, acute kidney injury [AKI], gastrointestinal bleeding, necrotizing enterocolitis [NEC]). (See <a class="local">'Choice of regimen'</a> above and <a class="local">'Comparative data'</a> above and <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent2">Contraindications to <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> and <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">indomethacin</a> include AKI/oliguria, gastrointestinal bleeding, NEC (proven or suspected), thrombocytopenia and/or coagulopathy, acute infection, and ductal-dependent congenital heart disease (CHD). In most of these circumstances, if the infant requires pharmacotherapy for PDA closure, <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a> (paracetamol) can be used. The exception is infants with ductal-dependent CHD who should not be given medications to close the PDA. (See <a class="local">'Contraindications'</a> above and  <a class="medical medical_review" href="/z/d/html/5774.html" rel="external">"Identifying newborns with critical congenital heart disease", section on 'Ductal-dependent lesions'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dosing</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Ibuprofen</strong> – The standard-dose <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> regimen consists of an initial dose of 10 mg/kg given enterally or IV followed by two additional doses of 5 mg/kg given at 24-hour intervals. The high-dose regimen consists of an initial dose of 15 to 20 mg/kg given enterally of IV followed by two additional doses of 7.5 to 10 mg/kg administered at 12- to 24-hour intervals. The high-dose regimen has a higher success rate but also has a higher risk of side effects. In our practice, we use the standard-dose regimen. (See <a class="local">'Dose'</a> above.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Acetaminophen</strong><strong> (paracetamol) </strong>– 15 mg/kg per dose given IV or enterally every six hours for three to seven days. (See <a class="local">'Acetaminophen (paracetamol)'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Indomethacin</strong> – Three doses of 0.2 mg/kg per dose given IV at 12-hour intervals. (See <a class="local">'Indomethacin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Response to therapy</strong> – The response to therapy is assessed based on the neonate's clinical status and repeat echocardiogram performed 24 to 48 hours after completion of the treatment course  (<a class="graphic graphic_algorithm graphicRef127115" href="/z/d/graphic/127115.html" rel="external">algorithm 1</a>). For infants who continue to have a hemodynamically significant PDA and who remain symptomatic (eg, ongoing ventilator dependence), we suggest a second course of treatment rather than proceeding with an invasive closure procedure (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Response to therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who fail medical therapy</strong> – For patients who fail to respond to two courses of therapy, subsequent treatment courses are unlikely to close the PDA. If the infant remains symptomatic from the PDA (eg, ventilator-dependent), options for definitive closure include surgical ligation or transcatheter occlusion. The choice between these is dependent on the expertise available at the center. (See <a class="local">'Procedures to close the PDA'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome</strong> – Preterm infants with clinically significant PDAs have a higher risk of mortality and morbidity compared with neonates of similar gestational age and birth weight without PDAs. Outcomes are generally worse for infants who require surgical ligation, which likely reflects that this is a more severely compromised patient population. (See <a class="local">'Outcome'</a> above and  <a class="medical medical_review" href="/z/d/html/5057.html" rel="external">"Patent ductus arteriosus (PDA) in preterm infants: Clinical features and diagnosis", section on 'Consequences of a PDA'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hamrick SEG, Sallmon H, Rose AT, et al. Patent Ductus Arteriosus of the Preterm Infant. Pediatrics 2020; 146.</a></li><li><a class="nounderline abstract_t">Mitra S, Weisz D, Jain A, Jong G'. Management of the patent ductus arteriosus in preterm infants. Paediatr Child Health 2022; 27:63.</a></li><li><a class="nounderline abstract_t">Runte KE, Flyer JN, Edwards EM, et al. Variation of Patent Ductus Arteriosus Treatment in Very Low Birth Weight Infants. Pediatrics 2021; 148.</a></li><li><a class="nounderline abstract_t">Sung SI, Lee MH, Ahn SY, et al. Effect of Nonintervention vs Oral Ibuprofen in Patent Ductus Arteriosus in Preterm Infants: A Randomized Clinical Trial. JAMA Pediatr 2020; 174:755.</a></li><li><a class="nounderline abstract_t">El-Khuffash A, Bussmann N, Breatnach CR, et al. A Pilot Randomized Controlled Trial of Early Targeted Patent Ductus Arteriosus Treatment Using a Risk Based Severity Score (The PDA RCT). J Pediatr 2021; 229:127.</a></li><li><a class="nounderline abstract_t">Clyman RI, Liebowitz M, Kaempf J, et al. PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age. J Pediatr 2019; 205:41.</a></li><li><a class="nounderline abstract_t">Rozé JC, Cambonie G, Le Thuaut A, et al. Effect of Early Targeted Treatment of Ductus Arteriosus with Ibuprofen on Survival Without Cerebral Palsy at 2 Years in Infants with Extreme Prematurity: A Randomized Clinical Trial. J Pediatr 2021; 233:33.</a></li><li><a class="nounderline abstract_t">Hundscheid T, Onland W, Kooi EMW, et al. Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus. N Engl J Med 2023; 388:980.</a></li><li><a class="nounderline abstract_t">Mitra S, Scrivens A, von Kursell AM, Disher T. Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants. Cochrane Database Syst Rev 2020; 12:CD013278.</a></li><li><a class="nounderline abstract_t">Gupta S, Subhedar NV, Bell JL, et al. Trial of Selective Early Treatment of Patent Ductus Arteriosus with Ibuprofen. N Engl J Med 2024; 390:314.</a></li><li><a class="nounderline abstract_t">Mirea L, Sankaran K, Seshia M, et al. Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias. J Pediatr 2012; 161:689.</a></li><li><a class="nounderline abstract_t">Hagadorn JI, Bennett MV, Brownell EA, et al. Covariation of Neonatal Intensive Care Unit-Level Patent Ductus Arteriosus Management and In-Neonatal Intensive Care Unit Outcomes Following Preterm Birth. J Pediatr 2018; 203:225.</a></li><li><a class="nounderline abstract_t">Madan JC, Kendrick D, Hagadorn JI, et al. Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome. Pediatrics 2009; 123:674.</a></li><li><a class="nounderline abstract_t">Alexander F, Chiu L, Kroh M, et al. Analysis of outcome in 298 extremely low-birth-weight infants with patent ductus arteriosus. J Pediatr Surg 2009; 44:112.</a></li><li><a class="nounderline abstract_t">Janz-Robinson EM, Badawi N, Walker K, et al. Neurodevelopmental Outcomes of Premature Infants Treated for Patent Ductus Arteriosus: A Population-Based Cohort Study. J Pediatr 2015; 167:1025.</a></li><li><a class="nounderline abstract_t">Relangi D, Somashekar S, Jain D, et al. Changes in Patent Ductus Arteriosus Treatment Strategy and Respiratory Outcomes in Premature Infants. J Pediatr 2021; 235:58.</a></li><li><a class="nounderline abstract_t">Altit G, Saeed S, Beltempo M, et al. Outcomes of Extremely Premature Infants Comparing Patent Ductus Arteriosus Management Approaches. J Pediatr 2021; 235:49.</a></li><li><a class="nounderline abstract_t">Kaempf JW, Wu YX, Kaempf AJ, et al. What happens when the patent ductus arteriosus is treated less aggressively in very low birth weight infants? J Perinatol 2012; 32:344.</a></li><li><a class="nounderline abstract_t">Sung SI, Chang YS, Chun JY, et al. Mandatory Closure Versus Nonintervention for Patent Ductus Arteriosus in Very Preterm Infants. J Pediatr 2016; 177:66.</a></li><li><a class="nounderline abstract_t">Slaughter JL, Reagan PB, Newman TB, Klebanoff MA. Comparative Effectiveness of Nonsteroidal Anti-inflammatory Drug Treatment vs No Treatment for Patent Ductus Arteriosus in Preterm Infants. JAMA Pediatr 2017; 171:e164354.</a></li><li><a class="nounderline abstract_t">Semberova J, Sirc J, Miletin J, et al. Spontaneous Closure of Patent Ductus Arteriosus in Infants ≤1500 g. Pediatrics 2017; 140.</a></li><li><a class="nounderline abstract_t">Liebowitz M, Clyman RI. Prophylactic Indomethacin Compared with Delayed Conservative Management of the Patent Ductus Arteriosus in Extremely Preterm Infants: Effects on Neonatal Outcomes. J Pediatr 2017; 187:119.</a></li><li><a class="nounderline abstract_t">de Carvalho Nunes G, Wutthigate P, Simoneau J, et al. Natural evolution of the patent ductus arteriosus in the extremely premature newborn and respiratory outcomes. J Perinatol 2022; 42:642.</a></li><li><a class="nounderline abstract_t">Isayama T, Kusuda S, Reichman B, et al. Neonatal Intensive Care Unit-Level Patent Ductus Arteriosus Treatment Rates and Outcomes in Infants Born Extremely Preterm. J Pediatr 2020; 220:34.</a></li><li><a class="nounderline abstract_t">Stephens BE, Gargus RA, Walden RV, et al. Fluid regimens in the first week of life may increase risk of patent ductus arteriosus in extremely low birth weight infants. J Perinatol 2008; 28:123.</a></li><li><a class="nounderline abstract_t">Green TP, Thompson TR, Johnson DE, Lock JE. Furosemide promotes patent ductus arteriosus in premature infants with the respiratory-distress syndrome. N Engl J Med 1983; 308:743.</a></li><li><a class="nounderline abstract_t">Clyman RI, Hills NK, Liebowitz M, Johng S. Relationship between Duration of Infant Exposure to a Moderate-to-Large Patent Ductus Arteriosus Shunt and the Risk of Developing Bronchopulmonary Dysplasia or Death Before 36 Weeks. Am J Perinatol 2020; 37:216.</a></li><li class="breakAll">Guidelines for PDA Screening and Management in Extremely Preterm Neonates. In University of Iowa's NICU Handbook. Available at: https://www.healthcare.uiowa.edu/marcom/uichildrens/neonatology-handbook/PDA-Screening-and-Management-Guidelines.pdf (Accessed on June 27, 2023).</li><li><a class="nounderline abstract_t">Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev 2020; 2:CD003481.</a></li><li><a class="nounderline abstract_t">Evans P, O'Reilly D, Flyer JN, et al. Indomethacin for symptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev 2021; 1:CD013133.</a></li><li><a class="nounderline abstract_t">Ohlsson A, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database Syst Rev 2020; 1:CD010061.</a></li><li><a class="nounderline abstract_t">Dani C, Poggi C, Mosca F, et al. Efficacy and safety of intravenous paracetamol in comparison to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: study protocol for a randomized control trial. Trials 2016; 17:182.</a></li><li><a class="nounderline abstract_t">Kumar A, Gosavi RS, Sundaram V, et al. Oral Paracetamol vs Oral Ibuprofen in Patent Ductus Arteriosus: A Randomized, Controlled, Noninferiority Trial. J Pediatr 2020; 222:79.</a></li><li><a class="nounderline abstract_t">Terrin G, Conte F, Oncel MY, et al. Paracetamol for the treatment of patent ductus arteriosus in preterm neonates: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2016; 101:F127.</a></li><li><a class="nounderline abstract_t">Dani C, Lista G, Bianchi S, et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. Eur J Pediatr 2021; 180:807.</a></li><li><a class="nounderline abstract_t">El-Farrash RA, El Shimy MS, El-Sakka AS, et al. Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. J Matern Fetal Neonatal Med 2019; 32:3647.</a></li><li><a class="nounderline abstract_t">Mitra S, Florez ID, Tamayo ME, et al. Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis. JAMA 2018; 319:1221.</a></li><li><a class="nounderline abstract_t">Eursiriwan S, Okascharoen C, Vallibhakara SA, et al. Comparison of Various Pharmacologic Agents in the Management of Hemodynamically Significant Patent Ductus Arteriosus in Preterm: A Network Meta-Analysis and Risk-Benefit Analysis. Biomed Hub 2022; 7:125.</a></li><li><a class="nounderline abstract_t">Gersony WM, Peckham GJ, Ellison RC, et al. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 1983; 102:895.</a></li><li><a class="nounderline abstract_t">Davis JM, Hendricks-Munoz KD, Hagberg D, Manning JA. The effects of indomethacin on renal function and intracranial hemorrhage in infants with patent ductus arteriosus. Dev Pharmacol Ther 1990; 14:15.</a></li><li><a class="nounderline abstract_t">Stavel M, Wong J, Cieslak Z, et al. Effect of prophylactic indomethacin administration and early feeding on spontaneous intestinal perforation in extremely low-birth-weight infants. J Perinatol 2017; 37:188.</a></li><li><a class="nounderline abstract_t">Zecca E, Romagnoli C, De Carolis MP, et al. Does Ibuprofen increase neonatal hyperbilirubinemia? Pediatrics 2009; 124:480.</a></li><li><a class="nounderline abstract_t">Rheinlaender C, Helfenstein D, Walch E, et al. Total serum bilirubin levels during cyclooxygenase inhibitor treatment for patent ductus arteriosus in preterm infants. Acta Paediatr 2009; 98:36.</a></li><li><a class="nounderline abstract_t">Desfrere L, Thibaut C, Kibleur Y, et al. Unbound bilirubin does not increase during ibuprofen treatment of patent ductus arteriosus in preterm infants. J Pediatr 2012; 160:258.</a></li><li><a class="nounderline abstract_t">Ahlfors CE. Effect of ibuprofen on bilirubin-albumin binding. J Pediatr 2004; 144:386.</a></li><li><a class="nounderline abstract_t">Christmann V, Liem KD, Semmekrot BA, van de Bor M. Changes in cerebral, renal and mesenteric blood flow velocity during continuous and bolus infusion of indomethacin. Acta Paediatr 2002; 91:440.</a></li><li><a class="nounderline abstract_t">Pezzati M, Vangi V, Biagiotti R, et al. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr 1999; 135:733.</a></li><li><a class="nounderline abstract_t">Kang NS, Yoo KH, Cheon H, et al. Indomethacin treatment decreases renal blood flow velocity in human neonates. Biol Neonate 1999; 76:261.</a></li><li><a class="nounderline abstract_t">Bhatt M, Petrova A, Mehta R. Does treatment of patent ductus arteriosus with cyclooxygenase inhibitors affect neonatal regional tissue oxygenation? Pediatr Cardiol 2012; 33:1307.</a></li><li><a class="nounderline abstract_t">Bellander M, Ley D, Polberger S, Hellström-Westas L. Tolerance to early human milk feeding is not compromised by indomethacin in preterm infants with persistent ductus arteriosus. Acta Paediatr 2003; 92:1074.</a></li><li><a class="nounderline abstract_t">Louis D, Torgalkar R, Shah J, et al. Enteral feeding during indomethacin treatment for patent ductus arteriosus: association with gastrointestinal outcomes. J Perinatol 2016; 36:544.</a></li><li><a class="nounderline abstract_t">Clyman R, Wickremasinghe A, Jhaveri N, et al. Enteral feeding during indomethacin and ibuprofen treatment of a patent ductus arteriosus. J Pediatr 2013; 163:406.</a></li><li><a class="nounderline abstract_t">Mitra S, de Boode WP, Weisz DE, Shah PS. Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane Systematic Reviews. Cochrane Database Syst Rev 2023; 4:CD013588.</a></li><li><a class="nounderline abstract_t">Van Overmeire B, Smets K, Lecoutere D, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000; 343:674.</a></li><li><a class="nounderline abstract_t">Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. Eur J Pediatr 2002; 161:202.</a></li><li><a class="nounderline abstract_t">Herrera C, Holberton J, Davis P. Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev 2007; :CD003480.</a></li><li><a class="nounderline abstract_t">Olowoyeye A, Nnamdi-Nwosu O, Manalastas M, Okwundu C. A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus. Pediatr Cardiol 2023; 44:748.</a></li><li><a class="nounderline abstract_t">Allegaert K, Anderson B, Simons S, van Overmeire B. Paracetamol to induce ductus arteriosus closure: is it valid? Arch Dis Child 2013; 98:462.</a></li><li><a class="nounderline abstract_t">Chorne N, Jegatheesan P, Lin E, et al. Risk factors for persistent ductus arteriosus patency during indomethacin treatment. J Pediatr 2007; 151:629.</a></li><li><a class="nounderline abstract_t">Kim ES, Kim EK, Choi CW, et al. Intrauterine inflammation as a risk factor for persistent ductus arteriosus patency after cyclooxygenase inhibition in extremely low birth weight infants. J Pediatr 2010; 157:745.</a></li><li><a class="nounderline abstract_t">Richards J, Johnson A, Fox G, Campbell M. A second course of ibuprofen is effective in the closure of a clinically significant PDA in ELBW infants. Pediatrics 2009; 124:e287.</a></li><li><a class="nounderline abstract_t">Keller RL, Clyman RI. Persistent Doppler flow predicts lack of response to multiple courses of indomethacin in premature infants with recurrent patent ductus arteriosus. Pediatrics 2003; 112:583.</a></li><li><a class="nounderline abstract_t">van der Lugt NM, Lopriore E, Bökenkamp R, et al. Repeated courses of ibuprofen are effective in closure of a patent ductus arteriosus. Eur J Pediatr 2012; 171:1673.</a></li><li><a class="nounderline abstract_t">Shah SD, Makker K, Zhang M, et al. Dual medication therapy (acetaminophen and ibuprofen) for the management of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. J Perinatol 2022; 42:1654.</a></li><li><a class="nounderline abstract_t">Deveci MF, Kaya H, Yurttutan S, et al. Combined (dual) drug therapy for the treatment of patent ductus arteriosus: last approach prior to ligation. Cardiol Young 2023; 33:1312.</a></li><li class="breakAll">Mavroudis C, Backer CL. Pediatric Cardiac Surgery, 3rd ed, Mosby-Year Book Inc, Philadelphia 2003. p.875.</li><li><a class="nounderline abstract_t">El-Khuffash AF, Jain A, McNamara PJ. Ligation of the patent ductus arteriosus in preterm infants: understanding the physiology. J Pediatr 2013; 162:1100.</a></li><li><a class="nounderline abstract_t">Clyman RI. Ibuprofen and patent ductus arteriosus. N Engl J Med 2000; 343:728.</a></li><li><a class="nounderline abstract_t">Clyman R, Cassady G, Kirklin JK, et al. The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial. J Pediatr 2009; 154:873.</a></li><li><a class="nounderline abstract_t">Giesinger RE, Bischoff AR, McNamara PJ. Anticipatory perioperative management for patent ductus arteriosus surgery: Understanding postligation cardiac syndrome. Congenit Heart Dis 2019; 14:311.</a></li><li><a class="nounderline abstract_t">Weisz DE, Mirea L, Rosenberg E, et al. Association of Patent Ductus Arteriosus Ligation With Death or Neurodevelopmental Impairment Among Extremely Preterm Infants. JAMA Pediatr 2017; 171:443.</a></li><li><a class="nounderline abstract_t">Weisz DE, Mirea L, Resende MHF, et al. Outcomes of Surgical Ligation after Unsuccessful Pharmacotherapy for Patent Ductus Arteriosus in Neonates Born Extremely Preterm. J Pediatr 2018; 195:292.</a></li><li><a class="nounderline abstract_t">Krishnappa S, Shah PS, Jain A, et al. Predictors of Early Extubation after Patent Ductus Arteriosus Ligation among Infants Born Extremely Preterm Dependent on Mechanical Ventilation. J Pediatr 2019; 214:222.</a></li><li><a class="nounderline abstract_t">Dimas VV, Takao C, Ing FF, et al. Outcomes of transcatheter occlusion of patent ductus arteriosus in infants weighing ≤ 6 kg. JACC Cardiovasc Interv 2010; 3:1295.</a></li><li><a class="nounderline abstract_t">Backes CH, Cheatham SL, Deyo GM, et al. Percutaneous Patent Ductus Arteriosus (PDA) Closure in Very Preterm Infants: Feasibility and Complications. J Am Heart Assoc 2016; 5.</a></li><li><a class="nounderline abstract_t">Francis E, Singhi AK, Lakshmivenkateshaiah S, Kumar RK. Transcatheter occlusion of patent ductus arteriosus in pre-term infants. JACC Cardiovasc Interv 2010; 3:550.</a></li><li><a class="nounderline abstract_t">Morville P, Douchin S, Bouvaist H, Dauphin C. Transcatheter occlusion of the patent ductus arteriosus in premature infants weighing less than 1200 g. Arch Dis Child Fetal Neonatal Ed 2018; 103:F198.</a></li><li><a class="nounderline abstract_t">Philip R, Waller BR, Chilakala S, et al. Hemodynamic and clinical consequences of early versus delayed closure of patent ductus arteriosus in extremely low birth weight infants. J Perinatol 2021; 41:100.</a></li><li><a class="nounderline abstract_t">Wei YJ, Ju YT, Hsieh ML, et al. Surgical ligation, not transcatheter closure, associated with a higher severity of bronchopulmonary dysplasia in extremely preterm infant intervened for patent ductus arteriosus. Pediatr Pulmonol 2023; 58:1221.</a></li><li class="breakAll">Premarket Approval (PMA): AMPLATZER Piccolo Occluder. U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P020024S052 (Accessed on December 04, 2020).</li><li><a class="nounderline abstract_t">Backes CH, Giesinger RE, Rivera BK, et al. Percutaneous Closure of the Patent Ductus Arteriosus in Very Low Weight Infants: Considerations Following US Food and Drug Administration Approval of a Novel Device. J Pediatr 2019; 213:218.</a></li><li><a class="nounderline abstract_t">Bischoff AR, Jasani B, Sathanandam SK, et al. Percutaneous Closure of Patent Ductus Arteriosus in Infants 1.5 kg or Less: A Meta-Analysis. J Pediatr 2021; 230:84.</a></li><li><a class="nounderline abstract_t">Sathanandam S, Gutfinger D, Morray B, et al. Consensus Guidelines for the Prevention and Management of Periprocedural Complications of Transcatheter Patent Ductus Arteriosus Closure with the Amplatzer Piccolo Occluder in Extremely Low Birth Weight Infants. Pediatr Cardiol 2021; 42:1258.</a></li><li><a class="nounderline abstract_t">Bischoff AR, Stanford AH, Aldoss O, et al. Left ventricular function before and after percutaneous patent ductus arteriosus closure in preterm infants. Pediatr Res 2023; 94:213.</a></li><li><a class="nounderline abstract_t">Cordero L, Nankervis CA, Delooze D, Giannone PJ. Indomethacin prophylaxis or expectant treatment of patent ductus arteriosus in extremely low birth weight infants? J Perinatol 2007; 27:158.</a></li><li><a class="nounderline abstract_t">Fowlie PW, Davis PG, McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 2010; :CD000174.</a></li><li><a class="nounderline abstract_t">Jensen EA, Dysart KC, Gantz MG, et al. Association between Use of Prophylactic Indomethacin and the Risk for Bronchopulmonary Dysplasia in Extremely Preterm Infants. J Pediatr 2017; 186:34.</a></li><li><a class="nounderline abstract_t">Abdi HH, Backes CH, Ball MK, et al. Prophylactic Indomethacin in extremely preterm infants: association with death or BPD and observed early serum creatinine levels. J Perinatol 2021; 41:749.</a></li><li><a class="nounderline abstract_t">Gillam-Krakauer M, Slaughter JC, Cotton RB, et al. Outcomes in infants &lt; 29 weeks of gestation following single-dose prophylactic indomethacin. J Perinatol 2021; 41:109.</a></li><li><a class="nounderline abstract_t">Ohlsson A, Shah SS. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2020; 1:CD004213.</a></li><li><a class="nounderline abstract_t">Härkin P, Härmä A, Aikio O, et al. Paracetamol Accelerates Closure of the Ductus Arteriosus after Premature Birth: A Randomized Trial. J Pediatr 2016; 177:72.</a></li><li><a class="nounderline abstract_t">Sellmer A, Bjerre JV, Schmidt MR, et al. Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3. Arch Dis Child Fetal Neonatal Ed 2013; 98:F505.</a></li><li><a class="nounderline abstract_t">Brooks JM, Travadi JN, Patole SK, et al. Is surgical ligation of patent ductus arteriosus necessary? The Western Australian experience of conservative management. Arch Dis Child Fetal Neonatal Ed 2005; 90:F235.</a></li><li><a class="nounderline abstract_t">Noori S, McCoy M, Friedlich P, et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics 2009; 123:e138.</a></li><li><a class="nounderline abstract_t">Kabra NS, Schmidt B, Roberts RS, et al. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr 2007; 150:229.</a></li><li><a class="nounderline abstract_t">Chorne N, Leonard C, Piecuch R, Clyman RI. Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics 2007; 119:1165.</a></li></ol></div><div id="topicVersionRevision">Topic 15814 Version 73.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33093140" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Patent Ductus Arteriosus of the Preterm Infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35273674" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Management of the patent ductus arteriosus in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34675131" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Variation of Patent Ductus Arteriosus Treatment in Very Low Birth Weight Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32539121" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Effect of Nonintervention vs Oral Ibuprofen in Patent Ductus Arteriosus in Preterm Infants: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33069668" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A Pilot Randomized Controlled Trial of Early Targeted Patent Ductus Arteriosus Treatment Using a Risk Based Severity Score (The PDA RCT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30340932" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33307111" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of Early Targeted Treatment of Ductus Arteriosus with Ibuprofen on Survival Without Cerebral Palsy at 2 Years in Infants with Extreme Prematurity: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36477458" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33301630" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38265644" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Trial of Selective Early Treatment of Patent Ductus Arteriosus with Ibuprofen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22703954" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30243544" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Covariation of Neonatal Intensive Care Unit-Level Patent Ductus Arteriosus Management and In-Neonatal Intensive Care Unit Outcomes Following Preterm Birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19171637" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19159727" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Analysis of outcome in 298 extremely low-birth-weight infants with patent ductus arteriosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26227439" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Neurodevelopmental Outcomes of Premature Infants Treated for Patent Ductus Arteriosus: A Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33894266" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Changes in Patent Ductus Arteriosus Treatment Strategy and Respiratory Outcomes in Premature Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33864797" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Outcomes of Extremely Premature Infants Comparing Patent Ductus Arteriosus Management Approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21818064" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : What happens when the patent ductus arteriosus is treated less aggressively in very low birth weight infants?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27453374" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Mandatory Closure Versus Nonintervention for Patent Ductus Arteriosus in Very Preterm Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28046188" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Comparative Effectiveness of Nonsteroidal Anti-inflammatory Drug Treatment vs No Treatment for Patent Ductus Arteriosus in Preterm Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28701390" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Spontaneous Closure of Patent Ductus Arteriosus in Infants≤1500 g.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28396025" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prophylactic Indomethacin Compared with Delayed Conservative Management of the Patent Ductus Arteriosus in Extremely Preterm Infants: Effects on Neonatal Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34815521" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Natural evolution of the patent ductus arteriosus in the extremely premature newborn and respiratory outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32145968" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Neonatal Intensive Care Unit-Level Patent Ductus Arteriosus Treatment Rates and Outcomes in Infants Born Extremely Preterm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18046337" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Fluid regimens in the first week of life may increase risk of patent ductus arteriosus in extremely low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6828120" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Furosemide promotes patent ductus arteriosus in premature infants with the respiratory-distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31600791" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Relationship between Duration of Infant Exposure to a Moderate-to-Large Patent Ductus Arteriosus Shunt and the Risk of Developing Bronchopulmonary Dysplasia or Death Before 36 Weeks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31600791" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Relationship between Duration of Infant Exposure to a Moderate-to-Large Patent Ductus Arteriosus Shunt and the Risk of Developing Bronchopulmonary Dysplasia or Death Before 36 Weeks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32045960" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33448032" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Indomethacin for symptomatic patent ductus arteriosus in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31985831" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27038924" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Efficacy and safety of intravenous paracetamol in comparison to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: study protocol for a randomized control trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32336479" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Oral Paracetamol vs Oral Ibuprofen in Patent Ductus Arteriosus: A Randomized, Controlled, Noninferiority Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26283668" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Paracetamol for the treatment of patent ductus arteriosus in preterm neonates: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32888085" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29695206" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29584842" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36465804" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparison of Various Pharmacologic Agents in the Management of Hemodynamically Significant Patent Ductus Arteriosus in Preterm: A Network Meta-Analysis and Risk-Benefit Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6343572" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2311476" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The effects of indomethacin on renal function and intracranial hemorrhage in infants with patent ductus arteriosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27763630" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effect of prophylactic indomethacin administration and early feeding on spontaneous intestinal perforation in extremely low-birth-weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19620202" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Does Ibuprofen increase neonatal hyperbilirubinemia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18764861" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Total serum bilirubin levels during cyclooxygenase inhibitor treatment for patent ductus arteriosus in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21875717" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Unbound bilirubin does not increase during ibuprofen treatment of patent ductus arteriosus in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15001951" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effect of ibuprofen on bilirubin-albumin binding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12061361" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Changes in cerebral, renal and mesenteric blood flow velocity during continuous and bolus infusion of indomethacin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10586177" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10516392" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Indomethacin treatment decreases renal blood flow velocity in human neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22466710" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Does treatment of patent ductus arteriosus with cyclooxygenase inhibitors affect neonatal regional tissue oxygenation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14599073" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Tolerance to early human milk feeding is not compromised by indomethacin in preterm infants with persistent ductus arteriosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26914015" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Enteral feeding during indomethacin treatment for patent ductus arteriosus: association with gastrointestinal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23472765" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Enteral feeding during indomethacin and ibuprofen treatment of a patent ductus arteriosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37039501" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane Systematic Reviews.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10974130" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12014386" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17443527" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36422654" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23606713" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Paracetamol to induce ductus arteriosus closure: is it valid?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18035143" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Risk factors for persistent ductus arteriosus patency during indomethacin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20598319" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Intrauterine inflammation as a risk factor for persistent ductus arteriosus patency after cyclooxygenase inhibition in extremely low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19651568" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A second course of ibuprofen is effective in the closure of a clinically significant PDA in ELBW infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12949288" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Persistent Doppler flow predicts lack of response to multiple courses of indomethacin in premature infants with recurrent patent ductus arteriosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22864766" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Repeated courses of ibuprofen are effective in closure of a patent ductus arteriosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36008521" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Dual medication therapy (acetaminophen and ibuprofen) for the management of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36472120" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Combined (dual) drug therapy for the treatment of patent ductus arteriosus: last approach prior to ligation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36472120" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Combined (dual) drug therapy for the treatment of patent ductus arteriosus: last approach prior to ligation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23410600" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Ligation of the patent ductus arteriosus in preterm infants: understanding the physiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10974138" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Ibuprofen and patent ductus arteriosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19324366" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30945807" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Anticipatory perioperative management for patent ductus arteriosus surgery: Understanding postligation cardiac syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28264088" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Association of Patent Ductus Arteriosus Ligation With Death or Neurodevelopmental Impairment Among Extremely Preterm Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29306492" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Outcomes of Surgical Ligation after Unsuccessful Pharmacotherapy for Patent Ductus Arteriosus in Neonates Born Extremely Preterm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31279574" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Predictors of Early Extubation after Patent Ductus Arteriosus Ligation among Infants Born Extremely Preterm Dependent on Mechanical Ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21232725" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Outcomes of transcatheter occlusion of patent ductus arteriosus in infants weighing≤6 kg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26873689" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Percutaneous Patent Ductus Arteriosus (PDA) Closure in Very Preterm Infants: Feasibility and Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20488412" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Transcatheter occlusion of patent ductus arteriosus in pre-term infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29066474" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Transcatheter occlusion of the patent ductus arteriosus in premature infants weighing less than 1200 g.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32792636" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Hemodynamic and clinical consequences of early versus delayed closure of patent ductus arteriosus in extremely low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36696083" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Surgical ligation, not transcatheter closure, associated with a higher severity of bronchopulmonary dysplasia in extremely preterm infant intervened for patent ductus arteriosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36696083" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Surgical ligation, not transcatheter closure, associated with a higher severity of bronchopulmonary dysplasia in extremely preterm infant intervened for patent ductus arteriosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31255391" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Percutaneous Closure of the Patent Ductus Arteriosus in Very Low Weight Infants: Considerations Following US Food and Drug Administration Approval of a Novel Device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33098843" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Percutaneous Closure of Patent Ductus Arteriosus in Infants 1.5 kg or Less: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34195869" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Consensus Guidelines for the Prevention and Management of Periprocedural Complications of Transcatheter Patent Ductus Arteriosus Closure with the Amplatzer Piccolo Occluder in Extremely Low Birth Weight Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36380071" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Left ventricular function before and after percutaneous patent ductus arteriosus closure in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17251986" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Indomethacin prophylaxis or expectant treatment of patent ductus arteriosus in extremely low birth weight infants?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20614421" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28258737" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Association between Use of Prophylactic Indomethacin and the Risk for Bronchopulmonary Dysplasia in Extremely Preterm Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33664466" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Prophylactic Indomethacin in extremely preterm infants: association with death or BPD and observed early serum creatinine levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32948814" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Outcomes in infants&lt;29 weeks of gestation following single-dose prophylactic indomethacin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31985838" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27215779" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Paracetamol Accelerates Closure of the Ductus Arteriosus after Premature Birth: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23893268" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846015" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Is surgical ligation of patent ductus arteriosus necessary? The Western Australian experience of conservative management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19117835" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Failure of ductus arteriosus closure is associated with increased mortality in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17307535" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17545385" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
